Join for free and get access to the buyside
Get insights from the world's most influential hedge fund investors direct to your inbox
- © 2025 Buyside Digest
- Privacy Policy
- Disclaimer
- Sitemap
- Terms of Service
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2024 Q4 | Jan 7, 2025 | Protean Select | - | 11.0% | ACAST.ST, AMBEA.ST, BAVA.CO, CARGOTEC.HE, CINT.ST, DEVYSER.ST, EMBRAC-B.ST, EVO.ST, GETI-B.ST, HEXA-B.ST, HM-B.ST, HUMBLE.ST, INTEA.ST, ITAB.ST, NVO, PROACT.ST, RAYSEARCH.ST, STEN-A.ST, TRYG.CO | Hedge Fund, Long/Short, Nordics, Pharmaceuticals, real estate, small caps | Significant focus on pharmaceutical investments including Novo Nordisk's Cagrisema trial results and Bavarian Nordic's vaccine franchise. The manager discusses pharma stocks trading on 5+ year growth potential and development timelines. | INTEA.ST AVGO|BYD|CRWD|MELI|MSFT|NFLX|NVDA|NVO|ORLY|SPOT BAVA.CO |
View |
| 2024 Q4 | Jan 7, 2025 | Protean Small Cap | - | 24.0% | ACAST.ST, AMBEA.ST, BAVA.CO, CGCBV.HE, CINT.ST, DEVYSER.ST, EMBRAC-B.ST, EVO.ST, GETI-B.ST, HEXA-B.ST, HM-B.ST, HUMBLE.ST, INTEA.ST, ITAB.ST, NOVO-B.CO, PROACT.ST, RAYSEARCH.ST, STORA-A.ST, TRYG.CO | growth, Nordics, real estate, small caps, Vaccines, value | The fund focuses on Nordic small caps as its core strategy, believing they offer superior return potential despite higher volatility. The manager emphasizes that small caps are their home turf where they benefit from being a small fund with the ability to be nimble and versatile. | INTEA.ST BAVA.CO |
View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| Apr 13, 2026 | Fund Letters | Protean Select | Bavarian Nordic | Health Care | Biotechnology | Bull | NASDAQ Copenhagen | biotechnology, Danish, margin expansion, Production Consolidation, Rabies, TBE, Travel Medicine, vaccines | View Pitch |
| Apr 13, 2026 | Fund Letters | Protean Small Cap | Bavarian Nordic | Health Care | Biotechnology | Bull | NASDAQ Copenhagen | acquisition target, biotechnology, climate change, Danish, margin expansion, Monkeypox, Rabies, TBE, Travel Medicine, vaccines | View Pitch |
| Oct 27, 2025 | Substack | Toff Cap Monday Monitor | Bavarian Nordic A/S | Health Care | Biotechnology | Bear | acquisition challenges, ATP, Bavarian Nordic, buyout offer, deal success, shareholder approval, shareholder opposition, strategic direction, undervalued, vaccines | View Pitch |
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| No investor data available. | ||||||||